Oral Green Tea Extract for Small Cell Lung Cancer

Status Available

Clinical Trial Summary

The purpose of this study is to determine whether green tea extract is safe for extensive-stage small lung cancer who achieved objective tumor response after first-line therapy.

Clinical Trial Description

Small-cell lung cancer accounts for 13 to 15% of all lung cancer and more than 60 to 70% of patients present with extensive disease (ED). Although etoposide plus cisplatin (EP) regimen has been the mainstay of ED-SCLC treatment, median overall survival is about 9 months, with 5 to 10% surviving two years and only 1% of patients achieving a long-term disease-free survival. To improve this outcome further, various attempts have been made, which included dose intensification with stem cell supports, maintenance therapy, and also searches for a better chemotherapy regimen.

Significant anticarcinogenic effects of green tea extract on various organs, such as skin, stomach, duodenum, colon, liver, pancreas, and lung in rodent models have been confirmed. Recent scientific investigations have identified the active chemical compounds in green tea designated tea polyphenols or catechins. Epigallocatechin-3-gallate (EGCG) is the major catechin in tea.An investigation about the effects of EGCG on human SCLC cells revealed that EGCG had similar anti-tumor effects on drug-sensitive (H69) and drug-resistant (H69VP) SCLC cells. Thus, the investigators conduct this phase I trial, the objectives of this trial were to study the side effects and best dose of of EGCG in treating patients with small-cell lung cancer who achieved objective tumor response after first-line therapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01317953
Study type	Expanded Access
Source	Shandong Cancer Hospital and Institute
Contact	Xindong Sun, M.D.
Phone	0086-053167626141
Email	zhx7152028@yahoo.com.cn
Status	Available
Phase

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05882058` - DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers	Phase 2
Terminated	`NCT03963414` - A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC	Phase 1
Active, not recruiting	`NCT04358237` - Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.	Phase 1/Phase 2
Not yet recruiting	`NCT06419179` - Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)	Phase 2
Completed	`NCT02874664` - A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer	Phase 1
Completed	`NCT02397733` - Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL)	N/A
Recruiting	`NCT01977235` - Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer	Phase 2
Completed	`NCT00759824` - A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide	Phase 2
Active, not recruiting	`NCT03568097` - Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer	Phase 2
Withdrawn	`NCT02876081` - Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex	Phase 2
Recruiting	`NCT06247605` - A Phase IIII Study of AL8326 in Small Cell Lung Cancer	Phase 3
Recruiting	`NCT04996771` - Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer	Phase 1/Phase 2
Terminated	`NCT03662074` - Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer	Phase 2
Completed	`NCT03232593` - A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
Completed	`NCT01941316` - Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients	Phase 1/Phase 2
Terminated	`NCT01574300` - Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
Recruiting	`NCT06131840` - A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05683977` - A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
Recruiting	`NCT04620837` - Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy	Phase 2
Recruiting	`NCT05329623` - A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.	Phase 1